Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2022 Earnings Call Transcript
Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) Q4 2022 Earnings Call Transcript February 16, 2023
Operator: Good day, and welcome to the Ironwood Pharmaceuticals Q4 and Full Year 2022 Investor Update Conference Call. Today's call is being recorded. . Thank you. And I would now like to turn the conference over to Matt Roache, Director of Investor Relations. Please go ahead.
Matt Roache: Thank you, Savanna. Good morning, and thanks for joining us for our fourth quarter and full year 2022 investor update. Our press release issued this morning can be found on our website. Today's call and accompanying slides include forward-looking statements. Such statements involve risks and uncertainties that may cause actual results to differ materially. A discussion of these statements and risk factors is available on the current safe harbor statement slide as well as under the heading, Risk Factors, in our annual report on Form 10-K for the year ended December 31, 2021, and in our future SEC filings. All forward-looking statements speak as of the day of this presentation, and we undertake no obligation to update such statements.
Also included are non-GAAP financial measures, which should be considered only as a supplement to and not a substitute for or superior to GAAP measures. To the extent applicable, please refer to the tables at the end of our press release for reconciliations of these measures to the most directly comparable GAAP measures. During today's call, Tom McCourt, our CEO, will review our strategic priorities and provide an update on the commercial performance of LINZESS. Mike Shetzline, our Chief Medical Officer, will discuss our pipeline. And Sravan Emany, our Chief Financial Officer, will review our financial results and guidance. Today's webcast includes slides. So for those of you dialing in, please go to the Events section of our website to access the accompanying slides separately.
With that, I'll turn the call over to Tom.
Thomas McCourt: Thanks, Matt. Good morning, everyone, and thanks for joining us today. As we begin 2023, our commitment to developing and advancing innovative solutions in the area of high unmet need in GI is as strong as ever. Looking back in the past year, we have made -- we made important progress in advancing the treatment of GI diseases, while redefining standard of care for patients. I'm very proud of the Ironwood team. And thanks to their hard work and dedication, we closed 2022 with a lot to be proud of. You've heard us talk about our focused approach based on 3 strategic priorities, where we seek to maximize LINZESS, strengthen and progress our innovative GI portfolio and deliver sustained profits and generate cash flow.
I'm delighted to say that we continue to drive strong LINZESS prescription demand growth, delivered on our full year adjusted EBITDA guidance, and we made strides across all 3 of our key strategic pillars. I remain confident in our strategy and believe we are well positioned for even greater success in 2023. Let's begin on Slide 6, with a quick overview of some of the key achievements against our strategic priorities for 2022 and what we expect in 2023. First, maximize LINZESS. LINZESS continues to see strong prescription demand growth, profitability and widespread acceptance among health care practitioners as the leading branded prescription treatment for adults with IBS-C and chronic idiopathic constipation. In 2022, prescription demand increased more than 9% year-over-year.
The brand continued to demonstrate market leadership by achieving an all-time high in new patient starts, which is a lead indicator for its future growth potential, and growing TRx market share, which reached an all-time high of 45% as of the end of December. As we announced earlier this week, we are pleased that the FDA granted a priority review of our sNDA for functional constipation in pediatric patients ages 6 to 17 and assigned a PDUFA date of June 14, 2023. We're particularly excited about the potential to expand the clinical utility of LINZESS to this underserved patient population. And we plan to leverage a focused investment to drive growth and improve brand margins over time. Next, strengthen and progress our innovative GI portfolio, starting with CNP-104, the potential disease-modifying treatment for primary biliary cholangitis.
In 2022, COUR Pharmaceuticals initiated a proof-of-concept study in PBC, which will assess the safety, tolerability, pharmacodynamic effect and efficacy. We also kicked off study start activities at the end of 2022 for the IW-3300, Ironwood's wholly-owned GC-C agonist for its potential treatment of visceral pain conditions, such as interstitial cystitis and bladder pain syndrome. We anticipate several exciting opportunities to advance the value potential of our pipeline this year. First, we expect early data in the second half of the year from patients enrolled into the clinical study for CNP-104. Second, we expect to begin patient dosing for a proof-of-concept study in the interstitial cystitis and bladder pain syndrome for IW-3300 in the near term.
Finally, we continue to actively evaluate opportunities to strengthen our portfolio, and we see several potential attractive opportunities in the market that could benefit from Ironwood's expertise in GI. Our third strategic priority is to deliver sustained profits and generate cash flow. We delivered on our guidance of over $250 million in adjusted EBITDA and ended the year with $656 million in cash and cash equivalents on the balance sheet, after deploying nearly $250 million in 2022 by completing our share repurchase program and repaying the principal on our '22 convertible notes. We are in a fortunate position of being a profitable biopharma company with a highly skilled and experienced team in the management of gastrointestinal diseases and a strong and growing cash balance.
We believe we're well positioned to execute on our strategy as we strive to become the leading GI health care company in the U.S. Now let's talk a bit more about the performance of LINZESS on Slide 7. As you can see on the left side of Slide 7, the performance of LINZESS has been remarkable, as we continue to see a robust linear growth trajectory. Over time, the strong prescription demand growth for LINZESS has been supported by a combination of high treatment satisfaction, updated clinical guideline support and class-leading formulary access. We continue to see an acceleration of appropriate new adult patient starts and anticipate this will be augmented in the future, should the FDA approve an indication for functional constipation in patients ages 6 to 17.
Photo by Myriam Zilles on Unsplash
We believe the pediatric opportunity, if approved, could expand the market potential for LINZESS as functional constipation affects roughly 6 million 6- to 17-year-old children and adolescents in the U.S. This is incremental to the need that still exists amongst approximately 40 million adults in the U.S. that suffer from IBS and chronic constipation. LINZESS is well positioned to be the branded market leader across both its current and potential future indications. Looking ahead, we're confident in our strategy and in our future. We believe the investments we're making in the brand and in our pipeline position our company for long-term growth. I would like to say a very big thank you to all the Ironwood employees who have laid the groundwork for continued momentum and strong execution against our strategic priorities as we continue to make meaningful impact on patients' lives.
I would now like to turn the call over to Mike to discuss our pipeline. Mike?
Michael Shetzline: Thanks, Tom, and good morning, everyone. We continue to make progress across our 3 pipeline programs. I'll begin with our linaclotide pediatric program on Slide 9. As Tom mentioned, we're thrilled that the FDA granted priority review for the LINZESS sNDA for functional constipation in children and adolescents 6 to 17 years of age, which could potentially lead to a commercial launch in June. If approved, LINZESS would be the first and only prescription therapy to treat this patient population. A new pediatric indication would further reinforce the strong clinical profile of LINZESS. I'm proud of the team's accomplishments as we continue to seek opportunities to broaden the clinical utility of LINZESS and redefine the standard of care for this patient group.
We look forward to presenting the Phase III data at the Digestive Disease Week meeting in May of this year. CNP-104, next, for the potential treatment of PBC, which affects an estimated 130,000 people in the U.S. As we've discussed previously, the strong immunology underpinning the CNP program is focused on targeting the specific PDC-E2 antigen responsible for the pathology of PBC. Therefore, there is an opportunity to assess PDC-E2-specific T cell responses, which should be a lead indicator of clinical benefit. We expect to assess T cell responses in patients dosed with CNP-104 in the second half of 2023. This early T cell data will inform the timing of top line and potential option exercise. We're excited about the CNP-104 because it is truly a precision medicine, and it introduces a potentially new game-changing asset for PBC patients, as there are no therapies on the market today that address the root cause of the autoimmune destruction of the bile ducts in PBC.
We'll provide updates on the program progress throughout this year. Moving on to IW-3300, a wholly-owned Ironwood asset for the potential treatment of interstitial cystitis and bladder pain syndrome. There's a significant unmet medical need in the area of IC-BPS as it affects an estimated 4 million to 12 million Americans, yet there are very few treatment options currently on the market or in development. In 2022, we successfully completed dosing studies in healthy volunteers, and we kicked off study start activities for the Phase II proof-of-concept study. We're prepared to begin dosing patients in the near term. This study has been thoughtfully designed to evaluate the potential impact of IW-3300 on visceral pain in patients with interstitial cystitis and bladder pain syndrome.
This trial will enroll patients with moderate to severe pain in a randomized, double-blind placebo-controlled study over 12 weeks. Patients who receive IW-3300 administered once daily, efficacy will be assessed based on change from baseline in the worst abdominal pain using an 11-point numeric rating scale, along with monitoring of urinary symptoms and other weekly and monthly assessments. We're excited to begin patient dosing and we look forward to providing updates as the study continues to advance. This is the first time the cross-talk hypothesis will be tested in humans, and we're proud to be at the forefront of clinical development in this area. With that, I'll turn the call over to Sravan.
Sravan Emany: Thanks, Mike, and good morning, everyone. I'll start with an update on LINZESS' performance. LINZESS U.S. net sales were $260 million in the fourth quarter of 2022, a decrease of 7% compared to the fourth quarter of 2021. Strong prescription demand growth of 9% was more than offset by price and inventory channel fluctuation. For full year 2022, as shown on Slide 11, LINZESS U.S. net sales were $1.002 billion, a slight decrease as compared to full year 2021. While full year net sales growth came in lower than our expectations for 2022, primarily due to inventory fluctuations in the retail channel, we remain confident in the long-term growth potential of LINZESS based on the strong prescription demand that we continue to see.
Turning to LINZESS brand profitability. Commercial margins in the fourth quarter of 2022 were 74% compared to 76% in the fourth quarter of 2021. For full year 2022, commercial margins were 73% versus 74% for full year 2021. Moving to Ironwood revenues. In Q4, Ironwood revenues were $107 million, driven primarily by the U.S. LINZESS collaboration revenues of $105 million. For the full year, Ironwood revenues were $411 million, with LINZESS U.S. collaboration revenues of $399 million. In the fourth quarter and for the full year, Ironwood recorded $23 million and $77 million of income tax expense, respectively, the majority of which was noncash. GAAP net income was $49 million in the fourth quarter and $175 million for the full year. Adjusted EBITDA was $69 million from Q4 and $252 million for the full year.
Throughout the year, we remained focused on our commitment to deliver strong profits and cash flows by driving continued robust LINZESS prescription demand and demonstrating disciplined expense management. As a result, I'm pleased that we were able to achieved our initial adjusted EBITDA guidance of greater than $250 million that we issued at the beginning of 2022. Next, cash and capital allocation. In the fourth quarter of 2022, we generated $79 million in cash flow from operations and $274 million for full year. We ended 2022 with $656 million in cash and cash equivalents after deploying nearly $250 million during the year by completing our share repurchase program and repaying the principal amount of our -- on our 2022 convertible notes.
We believe we are positioning our company for future success by maximizing LINZESS growth and actively pursuing innovative, highly differentiated GI assets to bolster our portfolio. We continue to take a balanced and disciplined approach to capital deployment. We remain focused on identifying and investing in opportunities that we believe will create value for our patients and shareholders over the long term. Turning to our 2023 guidance on Slide 12. As previously stated in January, we expect LINZESS U.S. net sales growth of between 3% and 5%, driven by high single-digit percent prescription demand growth. In addition, we expect to maintain our class-leading payer access with mid-single-digit price erosion. We expect Ironwood revenue of between $420 million and $435 million and adjusted EBITDA of greater than $250 million, which includes increased investment to advance our pipeline programs, CNP-104 and IW-3300.
To wrap up, we believe Ironwood is well positioned for continued growth, and we remain focused on advancing our 3 strategic priorities of maximizing LINZESS, strengthening and progressing our innovative GI portfolio and delivering sustained profits and generating cash flow. We have a blockbuster brand in LINZESS that continues to deliver impressive demand growth, with the potential to expand the market with a pediatric functional constipation indication beginning this year, if approved; an emerging pipeline with anticipated exciting milestones ahead; a strong balance sheet with over $650 million of cash and cash equivalents; and an accomplished management team with strong GI, commercial, drug development and M&A expertise. We are excited about the work ahead of us as we strive to make a difference for patients living with GI diseases and to deliver shareholder value.
Operator, you may now open up the line for questions.
See also 13 Top Performing Bitcoin Stocks in January and 20 Most Valuable Swedish Companies.
To continue reading the Q&A session, please click here.
